Drug firms argue against $1.2B Arkansas judgment

(AP)—A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics drug.

The state's countered during Thursday's hearing before the high court that Johnson & Johnson and a subsidiary were properly penalized for improper marketing of the drug Risperdal.

A Pulaski County jury ruled against the companies in 2012.

The companies also argued that the state brought the case under a Medicaid fraud law when there were no indications of improper reimbursements.

Sixty-five legislators filed a friend of the court brief saying the law was properly applied.

Johnson & Johnson separately agreed to a $2.2 billion federal settlement on similar claims.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Ark. judge affirms $181 million in legal fees

Feb 01, 2013

(AP)—An Arkansas judge says Johnson & Johnson must pay $181 million in fees to attorneys who successfully argued that the pharmaceutical company committed Medicaid fraud in the marketing of its antipsychotic drug Risperdal.

Report: J&J will pay $2.2B in Risperdal settlement

Jul 20, 2012

(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Authorities in US sue Novartis in kickback scheme

Jan 09, 2014

Novartis Pharmaceuticals Corp. paid kickbacks to a specialty pharmacy in exchange for recommending refills of a blood transfusion drug it produces, according to an amended complaint filed Wednesday in a civil case brought ...

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Recommended for you

Xtoro approved for swimmer's ear

23 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.